Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program

Myers, Gary L.; Miller, W. Greg; Coresh, Josef; Fleming, James H.; Greenberg, Neil; Greene, Tom; Hostetter, Thomas H.; Levey, Andrew S.; Panteghini, Mauro; Welch, Michael J.; Eckfeldt, John H.

doi:10.1373/clinchem.2005.0525144

Cited by 1,058 publications

(523 citation statements)

References 116 publications

Supporting

Mentioning

481

Contrasting

Unclassified

Order By: Relevance

“…The strengths of this study are: its large sample size, which allowed a robust estimate of between‐group differences in efficacy; the requirement for duplicate eGFR measurements during screening that ensured a population with stable renal status; and uptitration of dapagliflozin to its maximal approved dose (achieved in approximately 95% of patients). Lastly, the CKD‐epi formula used to estimate GFR in this study is considered more accurate and less likely to underestimate GFR at higher levels of renal function (≥ 60 mL/min/1.73 m 2 ) than the Modification of Diet in Renal Disease estimate 24, 25…”

Section: Discussionmentioning

confidence: 94%

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study

Scott

Morgan

Zimmer

et al. 2018

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimTo compare the efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin with the sodium‐glucose transporter‐2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency.Materials and MethodsPatients with HbA1c ≥7.0 to ≤9.5% (≥53 to ≤80 mmol/mol) and estimated glomerular filtration rate ≥60 to <90 mL/min/1.73m2 on metformin (≥1500 mg/d) ± sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks. A longitudinal data analysis model was used to test the primary hypothesis that sitagliptin is non‐inferior to dapagliflozin in reducing HbA1c at Week 24, with superiority to be tested if non‐inferiority is met. https://ClinicalTrials.gov NCT02532855.ResultsBaseline mean HbA1c (% [mmol/mol]) was 7.7 (60.9) and 7.8 (61.2), and mean eGFR (mL/min/1.73m2) was 79.4 and 76.9 for the sitagliptin and dapagliflozin groups, respectively. After 24 weeks, the between‐group difference in least squares mean (95% CI) changes from baseline in HbA1c was −0.15% (−0.26, −0.04) (−1.67 mmol/mol [−2.86, −0.48]), P = 0.006, meeting the prespecified criteria for declaring both non‐inferiority and superiority of sitagliptin versus dapagliflozin. The HbA1c goal of <7% (<53 mmol/mol) was met by 43% (sitagliptin) and 27% (dapagliflozin) of patients. No meaningful between‐group difference was observed in a pre‐specified analysis of 2‐hour incremental postprandial glucose excursion. A review of adverse events (AEs) was notable for a lower incidence of drug‐related AEs with sitagliptin compared with dapagliflozin.ConclusionsIn patients with type 2 diabetes, mild renal insufficiency and inadequate glycaemic control on metformin ± sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated.

show abstract

Section: Discussionmentioning

confidence: 94%

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study

Scott

Morgan

Zimmer

et al. 2018

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…It is recommended that laboratories report GFR as 460 ml min À1 instead of the actual value. 19 In this study, we reported the actual values obtained by MDRD and CKD-EPI to evaluate the study outcome. In addition, the abbreviated form of MDRD was used in this study.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of methods to estimate glomerular filtration rate versus actual drug clearance in patients with chronic spinal cord injury

Lee

Dang

2011

Spinal Cord

View full text Add to dashboard Cite

“…When it occurs, ARF is associated with a significant increase in risk for complications and death [3,4,5,6], as well as increased length of hospital stay and costs [3, 4]. Yet, despite the importance of ARF in decompensated CHF, there has been limited published data regarding this complication.…”

Section: Introductionmentioning

confidence: 99%

Risk for Acute Renal Failure in Patients Hospitalized for Decompensated Congestive Heart Failure

et al. 2007

View full text Add to dashboard Cite

Introduction: Congestive heart failure (CHF) is an important cause of hospital admissions and is associated with an increased risk for development of acute renal failure (ARF). The purpose of this study was to describe the incidence of ARF, to ascertain risk factors for its development, and to determine whether ARF impacts hospital outcomes. Methods: Review was conducted of 509 hospital medical records of patients hospitalized with a principal diagnosis of CHF during 2004. ARF was defined as an increase in serum creatinine of 0.5 mg/dl compared to the admission value. Multivariable analysis was used to identify independent predictors of ARF. Results: Most patients had reduced renal function at the time of admission with mean serum creatinine of 1.45 ± 0.72 and calculated creatinine clearance of 43.1 ml/min. ARF developed during the hospitalization in 21% of patients, with a peak increase in serum creatinine of 0.5–3.3 mg/dl. Most cases occurred on hospital days 4–6 (69.5% of cases). ARF was associated with increased risk for in-hospital mortality and increased length of hospital stay. Risk factors for ARF included diabetes, elevated admission serum creatinine and reduced serum sodium and echocardiographic demonstration of diastolic dysfunction. Neither diuretic nor ACEI/ARB treatment was associated with increased risk. Conclusion: ARF is a common complication among patients hospitalized for CHF, and is associated with increased risk for adverse outcomes. Certain clinical characteristics present at the time of admission help identify patients at increased risk.

show abstract

Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program

Cited by 1,058 publications

References 116 publications

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study

Evaluation of methods to estimate glomerular filtration rate versus actual drug clearance in patients with chronic spinal cord injury

Risk for Acute Renal Failure in Patients Hospitalized for Decompensated Congestive Heart Failure

Contact Info

Product

Resources

About